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Key Clinical Message
A 50-year-old female with ovarian cancer for 4 years presented with abdominal
pain. She started antibiotics for possible infection, and developed extravascular
hemolysis. All antigen detection tests were negative, but lectin panel suggested
Tk-activation. Additional laboratory testing in conjunction with blood bank is
essential to investigate rare cause of hemolysis.
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Introduction
Polyagglutination is the condition in which RBCs are
agglutinated by almost all normal adult ABO compatible
human sera, but not by cord blood sera or newborn’s sera
[1]. It occurs by alterations in RBC membrane glycopro-
tein structure by (a) the action of bacterial enzymes lead-
ing to cryptantigen exposure such as T, Tk, Th, or Tx,
(b) somatic mutation of an enzyme essential for forma-
tion of normal RBC membrane creating antigen such as
Tn, (c) inheritance of rare alleles for formation of RBC
membrane creating antigen such as Cad, Nor, or Hyde
Park, (d) undetermined cause in Va or Tr, or alternatively
(e) antibodies to some bacteria or their thermostable
products that adhere to RBCs causing agglutination with
or without antiglobulin serum [1–3].
Many antigenic determinants caused by bacterial
enzymes have been discovered, among which T cryptanti-
gen is the most common. Antibodies to those cryptanti-
gens are usually naturally occurring IgM antibodies that
are found in all normal adult sera but not in sera from
cord blood or newborns. Therefore, when cryptantigens
are exposed, polyagglutination can occur.
Most commonly, T-activation is a transient phenome-
non associated with bacterial infection such as pneumo-
cocci, streptococci, staphylococci, clostridia, Escherichia
coli, and Vibrio cholera [3]. Neuraminidase produced by
these bacteria removes N-acetyl neuroaminic acid residues
from RBC membrane sialoglycoproteins and exposes b-
linked galactosyl residues, the so-called T cryptantigen
(Fig. 1) [4]. T-activation in children is not uncommon
with some diseases. About 11–27% of infants with necro-
tizing enterocolitis are reported to have T-activation [5,
6], but hemolysis is rare. On the other hand, T-activation
in adults is rare and only 0.5% of hospitalized patients
have T-activation and less patients, 0.01% in the same
population, show polyagglutination [7]. Patients with
malignancies, especially gastrointestinal malignancy, and/
or sepsis are at higher risk and cryptantigens are detected
in 7.6% of those patients [8, 9]. Hemolysis is common in
adults with this condition and 70% of them have elevated
free serum Hgb. It is also associated with hemolytic ure-
mic syndrome with T-activation on renal endothelium,
red cells, and platelets.
Tk-activation is less common than T-activation and is
also a transient phenomenon associated with infection.
Bacteroides fragilis, Escherichia freundii, Escherichia coli,
Flavobacterium keratolyticus, Clostridium welchii, Group
D streptococci, and Pseudomonas species have been
reported as causative organisms [3, 10]. b-galactosidase of
bacterial origin cleaves galactose residue from paraglobo-
side on RBC membrane leading to N-acetylglucosamine
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exposure, the so-called Tk cryptantigen (Fig. 1) [4]. Tk-
activation is also reported in patients with necrotizing
enterocolitis, but the association with acquired B antigen
is suggested in patients with infection.
In most reported cases of cryptantigen activation in
adults, patients experienced intravascular hemolysis with
positive polyagglutination tests and positive agglutination
with selected lectins specific for each cryptantigen. How-
ever, the mechanism of hemolysis is not fully understood.
We here report a case with Tk-activation with negative
polyagglutination in the setting of extravascular hemolysis.
Case Presentation
A 50-year-old female presented to emergency department
(ED) at University of Michigan Health System in Septem-
ber 2012 complaining of increasing right lower quadrant
abdominal pain, malaise, nausea, vomiting, fever and
chills for 1 day, clear vaginal discharge for 2 weeks, and
recent lower leg swelling extending up to the right upper
thigh. The patient had a history of hysterectomy for a
benign indication in 1999, and bilateral salpingo-oopho-
rectomy, omentectomy, and tumor debulking for stage IV
high-grade papillary serous ovarian cancer in 2008. Subse-
quently, she received multiple courses of chemotherapy for
extensive metastasis, most recently completed etoposide
1 month prior to presentation. Other past medical history
was significant for hypertension, hypothyroidism, mitral
valve prolapse, and supraventricular tachycardia. Medica-
tions included nifedipine, levothyroxine, phenothiazine for
nausea and acetaminophen/oxycodone for pain control.
Physical examination demonstrated stable vital signs
with known tachycardia and regular rhythm, clear lung
fields, a known palpable-fixed mass in right lower quad-
rant, and a nodular firm mass on anterior vaginal wall.
Edema in the extremities was not present. Laboratory
data on presentation showed only mild anemia (Hgb
10.3 g/dL), mildly decreased WBC count with relative
neutrophilia (1.8 9 103/mm3, 87.2%), and platelet count
was within reference range. Metabolic panel and urinalysis
were normal. A test for glucose-6-phosphate dehydroge-
nase (G6PD) deficiency was negative.
Chest X-ray showed an apparent cavitary lesion
(2.1 9 2.3 cm) projecting over the posterior left eighth
rib in the region of the left hilum. A vague opacity suspi-
cious for an infectious process was also found in the lin-
gula of left lung. Abdominal ultrasound showed hepatic
metastatic lesions and enlarged hepatic lymph nodes.
Chest computerised tomography (CT) showed pulmonary
nodules and enlarged lymph nodes and a small pericardial
effusion. No pleural effusion was observed. Abdominal
CT revealed significant worsening of metastatic disease
with peritoneal carcinomatosis, urinary bladder wall
thickening suggestive of metastatic disease, multiple
enlarged abdominal and pelvic lymph nodes, hepatic
lesions, and small volume of ascites. Bilateral lower
extremity venous study showed no evidence of deep vein
thrombosis.
An infectious process was suspected, and Zosyn
(piperacillin/tazobactam) and vancomycin were adminis-
tered. On the next day, the patient developed hemolytic
anemia with Hgb of 7.6 g/dL, lactate Dehydrogenase
(LDH) of 1135 IU/L, haptoglobin of <10 mg/dL. Antibi-
otics were held for possible drug-induced immune hemo-
lytic anemia. At this point, she had mild renal
insufficiency (Cr 1.6 mg/dL) with aspartate amino trans-
ferase (AST) 60 IU/L and alanine amino transferase
(ALT) 16 IU/L, and total/direct/indirect bilirubin 7.3/0.6/
6.7 mg/dL. Ferritin was 16,500 ng/mL, iron was 106 lg/
dL, total iron-binding capacity was 206 lg/dL, and trans-
ferrin saturation was 51.5%. Prothrombin time (PT)/par-
tial thromboplastin time (PTT) were slightly increased to
14.1/34.9 sec, respectively, and international normalized
ratio was 1.3. Fibrinogen was slightly elevated to 453 mg/
dL and D-dimer was also elevated to 4.01 mg/L on the
following day. Reticulocyte count and percentage were
taken on hospital day 5 and day 8, which were 69.55 B/L
and 2.39%, and 124.27 B/L and 4.17%, respectively. A
stool occult blood test was negative. A peripheral smear
showed numerous spherocytes, burr cells, large platelets,
Figure 1. Cryptantigen exposure.
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and some Howell–Jolly bodies, but schistocytes were not
observed. (Fig. 2)
In blood bank testing, antibody detection tests includ-
ing low-ionic strength saline antibody screening,
polyethylene glycol-enhanced antibody screening, and acid
glycine elution were all negative. Cold agglutinin studies
were negative. Polyspecific, monospecific, and enhanced
direct antiglobulin tests (DAT) and enhanced DAT with
patient’s untreated and ficin-treated cells were also nega-
tive. Polyagglutination testing done as a part of our
enhanced DAT protocol with five ABO compatible adult
sera and two cord sera were negative, however, a lectin
panel (Table 1, HBS-Lectin Kit, Hemo bioscience, Dur-
ham, NC) revealed positivity (3+) with only Arachis hyp-
ogea suggesting Tk-activation.
Microbiology tests showed a few vancomycin-resistant
Enterococcus species in feces, and levofloxacin was started
from hospital day 3. The culture of ascites was not tested
because the ascites was most likely associated with her
condition with extensive pelvic metastasis of her ovarian
cancer. She was transfused with a total of 5 units of RBCs
(1 unit on hospital day 2, 3 units on day 4, 1 unit on day
5, Fig. 3) for her low Hgb. Her hemolysis subsided 2 days
after levofloxacin administration started supported by sta-
ble Hgb, decreasing LDH and total bilirubin (Fig. 3).
Chest X-ray (CXR) on day 4 revealed development of
patchy right basal opacity and streaky left basilar opacities
suggestive of pneumonia. The patient’s hemolysis and
other symptoms subsided and she was discharged in sta-
ble condition 9 days after levofloxacin was started.
Discussion
Our case developed hemolysis supported by decreased
Hgb and haptoglobin with increased reticulocyte count,
indirect bilirubin, and LDH. Moreover, it showed evi-
dence of extravascular hemolysis in the peripheral smear.
At the time of hemolysis, the peripheral smear showed
numerous spherocytes and some burr cells, Howell–Jolly
bodies, Dohle bodies, and large platelets, but schistocytes
were not observed. In nonhereditary conditions, extra-
vascular hemolysis is the most common cause of sphero-
cytes, whereas schistocytes indicate intravascular
hemolysis. Other possible causes of nonhereditary sphe-
rocytosis include severe hypophosphatemia, acute alco-
holism, septicemia with some bacteria, or following
severe burn injury. Of note, G6PD testing on this
patient was normal. Burr cells are mostly artifacts, but it
can occur with some medications, uremia, or mild
hemolysis in hypomagnesemia or hypophosphatemia.
Howell–Jolly bodies can be seen in megaloblastic anemia
or postsplenectomy. Dohle bodies in neutrophils are seen
in burns, infections, trauma, or neoplastic diseases. Our
patient’s peripheral smear findings are best explained by
extravascular hemolysis. Large platelets can be observed
in the condition with immune thrombocytopenia, disse-
minated intravascular coagulopathy (DIC), myeloprolifer-
ative disorders, preeclampsia, or recovery from transient
hypoplasia from chemotherapy. This may also support a
possibility of DIC. However, this patient had completed
chemotherapy for her cancer 1 month prior to the pre-
sentation. Therefore, large platelets may be due to recov-
ery from chemotherapy. The fact that her peripheral
smear on the day of discharge was still showing large
platelets supports this theory.
Table 1. Lectin panel interpretation.
Lectin Normal cells
Polyagglutinable cells
T Tk Tn Cad
Arachis hypogea  + +  
Salvia sclarea    + 
Salvia horminum    + +
Glycine soja  +  + +/
A                               B
A: Admission day 5: spherocytes, Burr cells, large platelets
B: Admission day 12: a few spherocytes and large platelets remained
Figure 2. Findings in peripheral smear.
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Cryptantigen exposure associated with infection is rare
but well developed concept of condition. Quite a few
cryptantigens have been described, and each antigen
agglutinates with some lectins in specific combination as
showing in Table 2 [1, 2, 11]. Our laboratory used a
commercially available lectin kit containing four lectins
shown in Table 1 (Arachis hypogea, Salvia sclarea, Salvia
horminum, Glycine soja). As shown in Table 2, reactivity
to only Arachis hypogea among these four lectins gives
rise to a possibility of Tx cryptantigen in addition to Tk
cryptantigen (same results in gray in Table 2). However,
Tx activation is most commonly seen in children and
reported to associate with infection by Streptococcus
pneumonia [11]. Therefore, Tx activation is less likely in
our case. Furthermore, I hypothesize that it may be possi-
ble to suspect which organism is causing the problem in
some cases depending on the type of exposed cryptanti-
gen that patient has.
The most commonly reported case scenario of hemoly-
sis with cryptantigen activation in adults is that of a
patient with intravascular hemolysis in the setting of
malignancy and/or sepsis, or hemolytic uremic syndrome,
Hgb*: Hemoglobin, T-BIL**: Total bilirubin, RET#: reticulocyte count, LDH†: lactate dehydrogenase, U#: unit, Txn##: transfusion
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Figure 3. Hospital course in laboratory tests.
Table 2. Reaction of lectins with cryptantigens.
Lectin Normal cells
Polyagglutinable cells
T Tk Tn Cad Th Tx Nor HEMPAS HbM Acquired B VA Tr
Arachis hypogea  + +   + +   w +/  +
Salvia sclarea    +  +       +
Salvia horminum    + +     w   +
Glycine soja  +  + +/   NT NT + NT NT NT
Glycine max  +  +      +   NT
Dolichos biflorus    + +      w/  
Griffonia simplicifolia I    +       +  NT
Griffonia simplicifolia II   +       +   +
Helix pomatia  +  + + NT NT  + + + + NT
Leonurus cardiaca  w/   +        NT
Medicago disciformis  +   NT +  NT NT + NT NT NT
Phaseolus limensis          NT +  NT
Polybrene   +  + + + NT NT NT NT NT NT
Vicia cretica  +    +    w   NT
Vicia hyrcanica  + + NT  + NT NT NT + NT NT NT
Vicia villosa  +  NT NT  NT NT NT + NT NT +
HEMPAS, congenital dyserythropoietic anemia, type II; HbM, hemoglobin M-Hyde park; w, weakly reactive; NT, not tested.
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mostly in conjunction with infection. Our patient had
only a few Enterococcus species in feces with relative neu-
trophilia but not absolute neutrophilia, and vague evi-
dence of infection on the chest X-ray. Blood and urine
cultures did not show any organisms. However, elevated
D-dimer with slightly high PT/PTT raised a possibility of
DIC. Fibrinogen was also slightly elevated, however,
increased fibrinogen does not rule out DIC because
fibrinogen is an acute phase reactant which is synthesized
in the liver and is often elevated in inflammatory condi-
tions. Therefore, it gives rise to a possibility that this
patient had mild acute DIC caused by infection. The
patient complained swollen leg at presentation, but it was
not observed in the hospital, and deep vein thrombosis
(DVT) scan of legs were negative. Thus, the high fibrino-
gen and D-dimer are not related to DVT, which may sup-
port possibility of DIC. Additionally, the fact that the
hemolysis subsided after levofloxacin was administered
also supports possibility of infection. Meichenin et al.
reported that Tk cryptantigen could be a colorectal carci-
noma-associated antigen in rats [12]. Similarly, the possi-
bility that ovarian cancer cells may express Tk
cryptantigen cannot be fully excluded, although it has not
been proven. Additionally, our case had been having
high-grade papillary serous ovarian cancer with extensive
metastasis for as long as 4 years prior to development of
hemolysis. Therefore, the infection may be taking at least
some roles to cause her new condition of cryptantigen
exposure.
The mechanism of hemolysis in the setting of cryptan-
tigen exposure is still not fully understood. The suggested
mechanisms include (a) cell destruction caused by anti-
gen–antibody reaction, (b) direct hemolytic action of bac-
terial enzymes and toxins [13], (c) altered interaction of
complement components with desialyated red cells [14],
(d) shortened survival of RBCs due to reduced membrane
sialic acid content [15, 16]. Furthermore, it is question-
able if cryptantigen exposure causes hemolysis. Many
reported cases with cryptantigen exposure did not have
hemolysis, but some cases showed intravascular hemolysis
[17–22]. And one report by Moores et al. showed a
patient with severe extravascular hemolysis associated
with T-activation [23]. Our patient had evidence of extra-
vascular hemolysis supported by peripheral smear findings
without any specific causes other than Tk-activation.
Other laboratory results including elevated AST and nor-
mal ALT, and undetected urinary hemosiderin and hemo-
globin also support extravascular hemolysis. Therefore,
intravascular red cell destruction due to complement acti-
vation resulted from anti-Tk is unlikely as a mechanism
of hemolysis in this case. Negative DAT also argues
against antibody or complement mediated hemolysis,
although the DAT can be negative when cryptantigens
absorb the corresponding antibodies and RBCs with those
fail to agglutinate [3]. Additionally, Crookston et al. ques-
tion a cause-and-effect relationship between anti-T and
hemolysis based on in vitro and in vivo studies and clini-
cal reports [17]. Direct action of bacterial enzymes and
toxins might play a role in hemolysis. However, our case
showed only a vague evidence of infection. Therefore, in
our case, the mechanism of extravascular hemolysis is
most likely a shortened survival of RBCs because of
altered RBC membrane glycoprotein structures due to
bacterial enzymes or toxins.
Lastly, the number of reports of hemolysis with Zosyn
(piperacillin/tazobactam) is increasing lately. Antibodies to
piperacillin or piperacillin/tazobactam have been reported
to cause both intra and extravascular hemolysis [24–27].
Our patient received one dose of Zosyn on hospital day
1. However, it was held because of the consideration of
drug-induced immune hemolysis (DIIH). Although DIIH
almost always demonstrates positive DAT, Pierce et al.
say that piperacillin does not bind strongly to RBC mem-
branes, such that drug-coated RBCs may be difficult to cre-
ate for in vitro testing. However, they also state that these
drug-dependent antibodies provoke precipitous intravas-
cular hemolysis due to complement fixation by interacting
with a neoantigen variably composed of RBC membrane
proteins and drug epitopes [28]. Our case showed negative
DAT even at the time of hemolysis, which is not common
for DIIH. Therefore, the possibility of DIIH cannot be
ruled out completely, but hemolysis from Tk-activation
may be a better explanation, especially because the positive
lectin panel was demonstrated in our case.
Conclusion
We reported a case of extravascular hemolysis most likely
due to Tk-activation. In our case, the mechanism of
hemolysis from Tk-activation is probably due to short-
ened RBC survival by altered RBC membrane sialic acid
content which can cause extravascular hemolysis rather
than due to complement activation by an antigen–anti-
body reaction which often causes intravascular hemolysis.
Additionally, when routine antibody detection tests are
negative in cases with clinically proven hemolysis, it is
important to investigate further by performing cold panel,
polyagglutination tests, and a lectin panel to detect rare
cause of hemolysis in conjunction with blood bank.
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